Medline (MDLN)

Medline (MDLN-Q) has shown impressive performance since its IPO last month, with a notable increase of 39.4%, although it is no longer at its peak. The company announced solid financial metrics through the first nine months of 2025, reporting a 9.8% growth in net sales and a 12.9% adjusted EBITDA margin, which indicates a positive trajectory despite facing some challenges. However, potential investors should be cautious, as current shareholders will maintain 80% of the voting rights, limiting the influence of new investors. The stock is trading at a substantial premium, closing 41% above its offering price, which some analysts feel is high given the company’s low double-digit growth prospects. The stock's valuation at approximately 45x PE suggests it's priced for perfection, advising a buying strategy only at lower price levels.